Text Size

Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Ironwood Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Forest Laboratories
ClinicalTrials.gov Identifier:
NCT01642914
First received: July 13, 2012
Last updated: May 31, 2013
Last verified: May 2013
History of Changes

July 13, 2012
May 31, 2013
August 2012
September 2013   (final data collection date for primary outcome measure)
9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder [ Time Frame: 12-week treatment period ] [ Designated as safety issue: No ]
A 9/12 Week CSBM 3+1 Responder is a patient who is a CSBM 3+1 Weekly Responder for at least 9 out of the 12 weeks of the Treatment Period. A CSBM 3+1 Weekly Responder is a patient who had a CSBM Weekly Frequency Rate that was 3 or greater and increased by 1 or more from baseline.
Same as current
Complete list of historical versions of study NCT01642914 on ClinicalTrials.gov Archive Site
  • Change from baseline in Abdominal Bloating [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Abdominal Bloating will be measured daily using an 11-point Numerical Rating Scale (NRS)
  • Abdominal Bloating will be measured daily using an 11-point Numerical Rating Scale (NRS) [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    A patient's 12-week CSBM frequency rate will be the CSBM rate (CSBMs/week) calculated over the 12-weeks of the Treatment Period.
  • Change from baseline Spontaneous Bowel Movement (SBM) Frequency Rate [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    A patient's 12-week SBM frequency rate will be the SBM rate (SBMs/week) calculated over the 12-weeks of the Treatment Period.
  • Change from baseline in Stool Consistency [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Bristol Stool Form Scale will be used by the patient to determine stool consistency
  • Change from baseline in Severity of Straining [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Severity of straining will be measured using a five-point ordinal scale.
  • Change from baseline in Constipation Severity [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Constipation severity will be measured weekly using a five-point ordinal scale.
  • Change from baseline in the Number of Days with a Spontaneous Bowel Movement ( SBM) [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    calculated as number of days with at least 1 Spontaneous Bowel Movement (SBM) during the Treatment Period divided by treatment duration of the patient multiplied by 7
  • Percentage change from baseline in Abdominal Bloating [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Abdominal Bloating will be measured daily using an 11-point Numerical Rating Scale (NRS)
  • Spontaneous Bowel Movement (SBM) within 24 hours after the first dose of investigational product [ Time Frame: reported within 24 hours of patient's first dose of investigational product ] [ Designated as safety issue: No ]
    A patient considered a responder if he/she has at least 1 Spontaneous Bowel Movement (SBM) within 24 hours after taking the first dose of investigational product
  • Complete Spontaneous Bowel Movement (CSBM) + 1 Responder [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    CSBM +1 Responder is a patient who has an increase in the 12 week CSBM Frequency Rate of 1 or more from baseline over the Treatment Period.
  • Abdominal Bloating 30% Responder [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    12-Week Abdominal Bloating 30% Responder is a patient who has an improvement in his/her 12-week abdominal bloating score of at least 30% compared to baseline.
  • Change in baseline in Abdominal Discomfort [ Time Frame: calculated daily over the 12 weeks of the patient's Treatment Period. ] [ Designated as safety issue: No ]
    Abdominal Discomfort will be measured daily using an 11-point Numerical Rating Scale (NRS)
  • Time to First Spontaneous Bowel Movement (SBM) After the First Dose of Investigational Product [ Time Frame: number of hours from the time of the first dose of investigational product ] [ Designated as safety issue: No ]
    Time to First SBM after First Dose of Investigational Product is defined as the number of hours elapsing from the time of the first dose of investigational product is taken to the occurrence of the first SBM
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Chronic Constipation and Prominent Abdominal Bloating at Baseline

The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating. This study includes an up to 3-week screening period and a 2-3 week pretreatment period. Patients who are eligible will be randomized to one of two doses of linaclotide or placebo for 12 weeks. This 12-week study will assess the effects of linaclotide on bowel movement frequency, as well as other abdominal and bowel symptoms of CC.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Chronic Constipation
  • Drug: Linaclotide 290 micrograms
    oral capsule, taken once daily each morning at least 30 minutes before breakfast
  • Drug: Linaclotide 145 micrograms
    oral capsule, taken once daily each morning at least 30 minutes before breakfast
  • Drug: Matching placebo
    oral capsule, taken once daily each morning at least 30 minutes before breakfast
  • Experimental: Linaclotide 290 micrograms
    Linaclotide 290 micrograms
    Intervention: Drug: Linaclotide 290 micrograms
  • Experimental: Linaclotide 145 Micrograms
    Linaclotide 145 micrograms
    Intervention: Drug: Linaclotide 145 micrograms
  • Placebo Comparator: Placebo
    Matching placebo
    Intervention: Drug: Matching placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
450
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has completed a colonoscopy according to the American Gastroenterological Association criteria with no clinically significant findings
  • Patient has successfully completed protocol procedures (with no clinically significant findings)

  • Patient meets protocol criteria for Chronic Constipation(CC): < 3 bowel movements per week and reports one or more of the following symptoms for at least 12 weeks:

    1. Straining during more than 25% of BMs
    2. Lumpy or hard stools during more than 25% of BMs
    3. Sensation of incomplete evacuation during more than 25% of BMs
  • Patient demonstrates continued chronic constipation and bloating through Pretreatment Period
  • Patient is compliant with Interactive voice response System (IVRS)

Exclusion Criteria:

  • Patient has a history of loose or watery stools
  • Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)
  • Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
  • Patient has any protocol-excluded or clinically significant medical or surgical history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01642914
LIN-MD-04
No
Forest Laboratories
Forest Laboratories
Ironwood Pharmaceuticals, Inc.
Study Director: Paul F. Eng, PhD Forest Laboratories
Forest Laboratories
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP